

05-15

**OFFICE OF THE COUNTY EXECUTIVE
ALL-EMPLOYEES MEMORANDUM**

DATE: April 28, 2015

**EMPLOYEE MEDICAL HEALTH PLAN (EMHP) OF
SUFFOLK COUNTY
PERSONALIZED MEDICINE PROGRAM**


As you will recall, All-Employees Memorandum 24-14 issued on December 23, 2014, announced that the EMHP Labor Management Committee implemented WellDyneRx's Personalized Medicine Program effective March 1, 2015.

The Personalized Medicine Program facilitates pharmacogenomics (study of how genes affects a person's response to drugs) testing, providing physicians with the information they need to make personalized prescribing decisions – selecting the right drug and the right dose more quickly, safely, and effectively. This personalized approach to prescribing:

- Enables more precise therapy and dosing decisions.
- Increases the probability of successful therapy.
- Lowers the risk of adverse effects.
- Reduces waste because patients get the right drug and the right dose faster.
- Reduces secondary costs such as hospitalization, absenteeism, and trial and error of different treatments.

The approval of dispensing the medications on the attached "Personalized Medicine Drug List" is contingent on the patient undergoing the appropriate genetic testing. For further information and reference, please visit the WellDyneRx website, emhp.welldynernx.com, or contact WellDyneRx directly at 1-855-799-6831 for the most current information. We recommend that you share this list with your physicians.

All drugs in this program **require** a Prior Authorization review by WellDyneRx. All drugs on the attached Personalized Medicine List may be amended from time to time so please check the website for the most current list. Either you or your physician can initiate the Prior Authorization process with WellDyneRx. Your physician will receive a Prior Authorization Form from WellDyneRx to complete and submit to WellDyneRx along with the chart notes and lab results or any other documentation required by WellDyneRx via fax to 888-473-7875 for review.



Dennis M. Cohen
Chief Deputy County Executive

Distribution:

One copy per employee/retiree-Attachments (1) Personalized Medicine Drug List

Personalized Medicine Drug List

DRUGS ON WELLDYNERX'S PERSONALIZED MEDICINE LIST	DISEASE STATE	PHARMACOGENOMIC TESTS
BLINCYTO	ONCOLOGY	Cytogenic or molecular genetic analysis to establish Ph- ALL
ERBITUX	ONCOLOGY	K-RAS mutation analysis
GILOTRIF	ONCOLOGY	EGFR mutation testing
GLEEVEC	LEUKEMIA	BCR-ABL Test, c-Kit (CD117) positive Test
HARVONI	HEPATITIS C	Hepatitis C Genotype 1 Test
HERCEPTIN	ONCOLOGY	Herceptest™ and Pathway® HER-2/neu (IHC assays) and PathVysiion® and HER2 FISH pharmDX™
INCIVEK	HEPATITIS C	Hepatitis C Genotype 1 Test
KADCYLA	ONCOLOGY	Herceptest™ and Pathway® HER-2/neu (IHC assays) and PathVysiion® and HER2 FISH pharmDX™
KALYDECO	CYSTIC FIBROSIS	CF Mutation Test
LYNPARZA	OVARIAN CANCER	gBRCAm Mutation Test
MEKINIST	MELANOMA	THxID BRAF Mutation Test
MYLERAN	CHRONIC MYELOGENOUS LEUKEMIA	Philadelphia chromosome-positive Test
OLYSIO	HEPATITIS C	Hepatitis C Genotype 1 Test
OPDIVO	ONCOLOGY	THXID BRAF Mutation Test
REVLIMID	ONCOLOGY	Cytogenetic or FISH testing
SELZENTRY	HIV	CCR5 co-receptor and CXCR4 co-receptor Tests
SOVALDI	HEPATITIS C	Hepatitis C Genotype 1, 2, 3, or 4 Test
SPRYCEL	ONCOLOGY	Philadelphia chromosome-positive Test
TAFINLAR	MELANOMA	ThxID BRAF Mutation Test
TRIUMEQ	HIV	COBAS® AmpliPrep/COBAS® TaqMan® HLA-B*5701 test
TYKERB	ONCOLOGY	HER2 Test
VECTIBIX	COLORECTAL CARCINOMA	KRAS MUTATION Analysis
VICTRELIS	HEPATITIS C	Hepatitis C Genotype 1 Test
VIEKIRA PAK	HEPATITIS C	Hepatitis C Genotype 1 Test
XALKORI	ONCOLOGY	Vysis ALK Break-Apart FISH Probe Kit test
ZELBORAF	MELANOMA	Cobas® 4800 BRAF V600 Mutation Test
ZIAGEN	HIV	HLA-B*5701 Genetic Test
ZYKADIA	ONCOLOGY	ANAPLASTIC LYMPHOMA KINASE POSITIVE Test